Crossmark

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation

Published Online: 2017-02-23

Published Print: 2017-12

Authors

Ott, Christian

Jumar, Agnes

Striepe, Kristina

Friedrich, Stefanie

Karg, Marina V.

Bramlage, Peter

Schmieder, Roland E. https://orcid.org/0000-0003-2356-5883
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02383238 at ClinicalTrials.gov

Documents that mention this clinical trial

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
https://doi.org/10.1186/s12933-017-0654-z

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
https://doi.org/10.1186/s12933-018-0770-4

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
https://doi.org/10.1186/s12933-017-0510-1
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2017-02-23

Version of Record valid from 2017-02-23
More Information

Article History

Received: 4 November 2016

Accepted: 5 February 2017

First Online: 23 February 2017

Document is current